Literature DB >> 24816643

Anti-HLA alloantibodies in surgical patients refractory to platelet transfusion.

Jeremy Ryan A Peña1, Susan L Saidman, Timothy C Girouard, Erin Meister, Walter H Dzik, Robert S Makar.   

Abstract

Alloimmune platelet refractoriness (alloPR) among actively bleeding surgical patients with thrombocytopenia represents a life-threatening problem. Here we present three cases in which surgical bleeding was complicated by life-threatening thrombocytopenia and alloPR. We demonstrate that the human leukocyte antigens (HLA) antibodies associated with alloPR are broadly reactive and in high concentration, are not removed by hemodilution, and are not absorbed by transfusion of multiple doses of platelet concentrates. HLA alloPR may be under-recognized among surgical patients. Research is needed to develop pre-operative screening methods that will identify patients in need of specialized platelet support using HLA compatible donor products.
© 2014 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24816643      PMCID: PMC4416418          DOI: 10.1002/ajh.23757

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  24 in total

Review 1.  Refractoriness to platelet transfusion.

Authors:  Paolo Rebulla
Journal:  Curr Opin Hematol       Date:  2002-11       Impact factor: 3.284

2.  HLA-DR expression by platelets in acute idiopathic thrombocytopenic purpura.

Authors:  L K Boshkov; J G Kelton; P F Halloran
Journal:  Br J Haematol       Date:  1992-08       Impact factor: 6.998

3.  Histocompatibility antigens of human plasma. Localization to the HLD-3 lipoprotein fraction.

Authors:  R H Aster; B H Miskovich; G E Rodey
Journal:  Transplantation       Date:  1973-09       Impact factor: 4.939

4.  Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions.

Authors: 
Journal:  N Engl J Med       Date:  1997-12-25       Impact factor: 91.245

5.  Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients.

Authors:  R A Montgomery; A A Zachary; L C Racusen; M S Leffell; K E King; J Burdick; W R Maley; L E Ratner
Journal:  Transplantation       Date:  2000-09-27       Impact factor: 4.939

6.  Platelet transfusion refractoriness caused by a mismatch in HLA-C antigens.

Authors:  Satoshi Saito; Satoshi Ota; Hideyuki Seshimo; Yuichiro Yamazaki; Setsuo Nomura; Toshihiro Ito; Jun Miki; Masao Ota; Hirofumi Fukushima; Hiroo Maeda
Journal:  Transfusion       Date:  2002-03       Impact factor: 3.157

7.  Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients.

Authors:  Sherrill J Slichter; Kathryn Davis; Helen Enright; Hayden Braine; Terry Gernsheimer; Kuo-Jang Kao; Thomas Kickler; Edward Lee; Janice McFarland; Jeffrey McCullough; Glenn Rodey; Charles A Schiffer; Robert Woodson
Journal:  Blood       Date:  2005-02-03       Impact factor: 22.113

8.  The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: implications for a transfusion-related acute lung injury risk reduction strategy.

Authors:  Darrell J Triulzi; Steven Kleinman; Ram M Kakaiya; Michael P Busch; Philip J Norris; Whitney R Steele; Simone A Glynn; Christopher D Hillyer; Patricia Carey; Jerome L Gottschall; Edward L Murphy; Jorge A Rios; Paul M Ness; David J Wright; Danielle Carrick; George B Schreiber
Journal:  Transfusion       Date:  2009-05-18       Impact factor: 3.157

9.  Platelet transfusion therapy for alloimmunized patients: selective mismatching for HLA B12, an antigen with variable expression on platelets.

Authors:  C A Schiffer; B O'Connell; E J Lee
Journal:  Blood       Date:  1989-08-15       Impact factor: 22.113

10.  Clinical and blood bank factors in the management of platelet refractoriness and alloimmunization.

Authors:  R C Friedberg; S F Donnelly; J C Boyd; L S Gray; P D Mintz
Journal:  Blood       Date:  1993-06-15       Impact factor: 22.113

View more
  4 in total

Review 1.  Anti-HLA antibody testing in hematology patients.

Authors:  Jeremy Ryan A Peña; Susan L Saidman
Journal:  Am J Hematol       Date:  2015-04       Impact factor: 10.047

2.  Generation of HLA-Universal iPSC-Derived Megakaryocytes and Platelets for Survival Under Refractoriness Conditions.

Authors:  Ann-Kathrin Börger; Dorothee Eicke; Christina Wolf; Christiane Gras; Susanne Aufderbeck; Kai Schulze; Lena Engels; Britta Eiz-Vesper; Axel Schambach; Carlos A Guzman; Nico Lachmann; Thomas Moritz; Ulrich Martin; Rainer Blasczyk; Constança Figueiredo
Journal:  Mol Med       Date:  2016-05-16       Impact factor: 6.354

3.  The Use of Splenectomy to Manage Platelet Transfusion Refractoriness due to Anti-Human Leukocyte Antibodies in Allogeneic Stem Cell Transplantation.

Authors:  Margherita Mauro; Francesco Camoglio; Pierluigi Piccoli; Massimiliano De Bortoli; Rita Balter; Anna Pegoraro; Simone Cesaro
Journal:  Pediatr Rep       Date:  2016-03-31

4.  Transfer to the clinic: refining forward programming of hPSCs to megakaryocytes for platelet production in bioreactors.

Authors:  Amanda L Evans; Amanda Dalby; Holly R Foster; Daniel Howard; Amie K Waller; Momal Taimoor; Moyra Lawrence; Souradip Mookerjee; Marcus Lehmann; Annie Burton; Jorge Valdez; Jonathan Thon; Joseph Italiano; Thomas Moreau; Cedric Ghevaert
Journal:  Blood Adv       Date:  2021-04-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.